Scientific Program 07.01.20 - 11.01.20, Eilat, Israel

Total Page:16

File Type:pdf, Size:1020Kb

Scientific Program 07.01.20 - 11.01.20, Eilat, Israel Scientific Program 07.01.20 - 11.01.20, Eilat, Israel The 20th Annual Meeting of the Israeli Society of Clinical Oncology and Radiotherapy הוועדה המארגנת ISCORT wishes to express its gratitude to the following companies Organizing Committee ISCORT 20 for their support of the 20th ISCORT Annual Meeting: נשיא הכנס: :President פרופ׳ ברוך ברנר Platinum Sponsor Baruch Brenner, MD מזכיר האונקולוגיה הרפואית: :Roche Secretary, Medical Oncology ד״ר נעם אסנה Gold Sponsor Noam Asna, MD מזכירת הרדיותרפיה: :AstraZeneca Secretary, Radiation Oncology ד״ר סבטלנה זלמנובה MSD Svetlana Zalmanova, MD Novartis הוועדה המדעית Scientific Committee ISCORT 20 Pfizer יו״ר: פרופ׳ אהרון סולקס Silver Sponsor Chairman: Aaron Sulkes, MD סגן יו״ר: פרופ׳ גל מרקל Assuta Deputy Chairman: Gal Markel, MD, PhD מזכיר: ד״ר אסף מור Secretary: Assaf Moore, MD Astellas ד״ר יאיר בר BMS Jair Bar, MD, PhD פרופ׳ גיל בר-סלע Eli Lilly Gil Bar-Sela, MD פרופ׳ אלברטו גביזון Alberto Gabizon, MD, PhD Medison פרופ׳ עידו וולף Ido Wolf, MD ד״ר מרק ויגודה Oncotest Rhenium Marc Wygoda, MD ד״ר אמיר זוננבליק Rafa Amir Sonnenblick, MD פרופ׳ ג‹אמל זידאן Sanofi Jamal Zidan, MD ד״ר אלונה זר Teva Alona Zer, MD פרופ׳ רינת ירושלמי Varian Rinat Yerushalmi, MD ד״ר דרור לימון Dror Limon, MD ד״ר מור מושקוביץ Bronze Sponsor Mor Moskovitz, MD ד״ר בלאן סאלם AAA Salem Billan, MD פרופ׳ טלי סיגל Ami Technologies Tali Siegal, MD פרופ׳ תמר ספרא Bayer Tamar Safra, MD פרופ׳ ביאטריס עוזיאלי Boehringer Ingelheim Beatrice Uziely, MD פרופ׳ אהרון פופובצר Aron Popovtzer, MD Desit פרופ׳ רפאל קטן Raphael Catane, MD ד״ר דניאל קייזמן Dexcel Pharma Daniel Keizman, MD ד״ר אלי רוזנבאום ISI Eli Rosenbaum, MD ד״ר אורה רוזנגרטן Janssen Ora Rosengarten, MD ד״ר קטרינה שולמן Merck Katerina Shulman, MD ד״ר עינת שחם-שמואלי Nanostring Einat Shacham-Shmueli, MD Neopharm החברה המארגנת Organizing Company Perrigo א.מ. כנסים בע"מ .Takeda I.M. Knasim Ltd חברים נכבדים, ,Dear friends and colleagues אנו מתכבדים להזמינכם להשתתף בכינוס של האיגוד הישראלי לאונקולוגיה We are honored to cordially invite you to participate in the 20th Annual Meeting קלינית ורדיותרפיה, ISCORT 20, אשר יתקיים באילת בין 7-11 לינואר of the Israel Society of Clinical Oncology and Radiotherapy (ISCORT), which will .2020 הנושא המרכזי בכינוס הוא ״עמיתים מעדכנים עמיתים״, שנבחר לאור ייחודו של s central theme will be׳be held in Eilat between January 7-11, 2020. The meeting which was selected as a result of the meeting’s ,״Colleagues Update Colleagues״ כנס ISCORT מכנסים אחרים; אין זה כנס המתמקד בתחום אחד באונקולוגיה ואין unique nature, which does not focus on a single issue nor is it devoted mainly זה כנס בו מאזינים מקומיים רבים מתקבצים כדי לשמוע מוביל דעה עולמי. כנס to learn from international opinion leaders. ISCORT is, in its essence, a meeting ISCORT במהותו הוא מפגש נעים ומפרה של עמיתים ישראליים, בו אונקולוגים of Israeli colleagues in which oncologists specializing in one field update their מתחום אחד מתעדכנים מעמיתיהם על ההתקדמויות האחרונות בתחום בו הם colleagues on the latest developments in their area of interest. The choice to emphasize this nature of ISCORT Meeting derived not only from a wish but rather מתמקצעים. הבחירה להבליט אופיו זה של כנס ISCORT נבעה לא רק מהרצון, from the ability; we have witnessed substantial progress in the Oncology specialty אלא גם מהיכולת; בשנים האחרונות התפתח מאד מקצוע האונקולוגיה בארץ, in Israel in recent years, with the formation of a cadre of many specialists in תוך התהוות שכבה של אנשי מקצוע רבים הניצבים בחזית העשייה בתחום the forefront of professional activity, who are also very capable of sharing their או תת-תחום בו הם עוסקים, ואשר בורכו ביכולת להעביר את הידע והניסיון knowledge and expertise with their colleagues. ISCORT serves therefore, as an הרב שצברו לעמיתיהם. במצב זה, רק מתבקש שכנס ISCORT יהווה את הבמה optimal platform for information exchange between Israeli colleagues. With this המיטבית לחילופי מידע בין עמיתים ישראליים. ברוח זו, שפת הכנס תהיה ככלל -spirit, the Meeting will be conducted in Hebrew, except for sessions with a non בעברית, להוציא ישיבות בהן יהיה מרצה אורח. .Israeli speaker In parallel with enriching the knowledge in main oncology fields, particularly those לצד העשרת הידע בתחומים המרכזיים באונקולוגיה, ובייחוד באלה בהם חלה in which substantial progress has taken place over the past year since the last התקדמות משמעותית בשנה שחלפה מכנס ISCORT הקודם, נבחרו השנה גם ISCORT meeting, we have chosen this year to update several cross cutting topics מספר נושאים חוצי-תחומים עדכניים, המסקרנים ומטרידים בו זמנית את מרבית which intrigue and concern most oncologists both in Israel and worldwide. Among האונקולוגים בארץ ובעולם. בין אלה נכללו המחירים האפשריים של בדיקות ,these, we have included sessions about the potential costs of cancer screening סקר, הביולוגיה והאימונולוגיה של מחלת הסרטן, והמחלה האוליגו-גרורתית. .cancer biology and immunology and oligometastatic disease Like prior organizing committees, we have also invested a major effort in creating בדומה לוועדות מארגנות קודמות, גם אנו השקענו מאמץ רב כדי לבנות תכנית an interesting and varied program. The meeting includes lectures, reviews מדעית מעניינת ומגוונת. הכינוס מורכב מהרצאות, סקירות של פרסומים of leading publications, multidisciplinary case presentations and discussions מובילים, דיוני מקרים רב-תחומיים, ודיונים בנושאים הנתונים במחלוקת. כמו on controversial issues. In addition, outstanding works will be presented by כן, יוצגו עבודות מצטיינות ממרכזים שונים בארץ, מתחומי מחקר קליני, תרגומי oncologists from various Israeli institutions on clinical, translational and basic ובסיסי. .science topics Notwithstanding the emphasis on the input of Israeli oncologists, we will also למרות הדגש על מרצים ישראליים, עדיין יכבדו אותנו בהשתתפותם גם אורחים be honored to welcome guests from abroad who will undoubtedly enrich our מחו״ל, אשר ללא ספק יעשירו את הבנתנו בנושאים מסוימים באונקולוגיה. understanding of specific topics in Oncology. We would like to express our special בהזדמנות זו נרצה להודות באופן מיוחד לוועדה המדעית בראשותם של פרופ׳ thanks to the Scientific Committee lead by Prof. Aaron Sulkes (chairman), Prof. Gal אהרון סולקס )יו״ר הועדה(, פרופ׳ גל מרקל )סגן יו״ר( וד״ר אסף מור )מזכיר(, על Markel (vice-chairman) and Dr. Assaf Moore (secretary) for their thorough work עבודה יסודית ביותר בבחירת התקצירים אשר יוצגו בכינוס. .and commitment in selecting the best abstracts to be presented at the meeting מצפים לכם באילת ומאחלים לכולם עניין והנאה כאחד. We look forward to meeting you in Eilat and wish you a pleasant and fruitful meeting. בברכה, ,Sincerely פרופ׳ ברוך ברנר ד״ר נעם אסנה ד״ר סבטלנה זלמנובה Prof. Baruch Brenner Dr. Noam Asna Dr. Svetlana Zalmanova נשיא הכינוס מזכיר האונקולוגיה מזכירת הרדיותרפיה (President Secretary (Medical Secretary (Radiotherapy Oncology) Oncology) Keynote Lecture Tuesday, January 7, 2020 Moderator: Miri Ziv Vice Chairman, Israel Cancer Association, 17.00-18.50 Opening Session Givatayim, Israel Moderator: Noam Asna, MD Barzilai Medical Center, Ashkelon, Israel 18.20-18.50 Cancer Screening: Benefits only? Otis Webb Brawley, MD 17.00-17.20 Welcome Johns Hopkins University, Baltimore, USA Baruch Brenner, MD Davidoff Center, Rabin Medical Center, Petach 19.30 Dinner Tikva, Israel Wilmosh Mermershtain, MD Chairman, ISCORT 17.20-17.30 Resident Recognition Award Avraham Kuten, MD Chair, Israel Cancer Association, Givatayim, Israel 17.30-18.20 Best ISCORT Abstracts and Publications Awards Moderator: Aaron Sulkes, MD Davidoff Center, Rabin Medical Center, Petach Tikva, Israel Radiation Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer Merav A. Ben David, MD Assuta Medical Center, Tel-Aviv, Israel Adaptation of Colon Cancer Cells to the Brain Microenvironment: The Role of IRS2 Ido Wolf, MD Sourasky Medical Center, Tel-Aviv, Israel Incidence and Risk Factors of Arterial Thromboembolism (ATE) and Venous Thromboembolism (VTE) in Non-Small Cell Lung Cancer (NSCLC) Alona Zer, MD Davidoff Center, Rabin Medical Center, Petach Tikva, Israel Best Publications 2019 09.50-10.30 Tumor Board - Esophageal Cancer Wednesday, January 8, 2020 Moderator: Sharon Pelles, MD Sourasky Medical Center, Tel-Aviv, Israel 07.30-08.10 Meet the Professor - SBRT Tarshish A Hall Panel: Alon Ben-Nun, MD, PhD Sheba Medical Center, Ramat-Gan, Israel Raphael Pfeffer, MD Assuta Medical Center, Tel-Aviv, Israel Marc Wygoda, MD Supported by Assuta Medical Centers Hadassah Medical Center, Jerusalem, Israel Gastro-Intestinal Malignancies - Part I Nirit Yarom, MD Shamir (Asaf Harofe) Medical Center, Tzrifin, Moderators: Ofer Purim, MD Israel Assuta Medical Center, Ashdod, Israel 10.30-10.45 Coffee Break Yaacov Lawrence, MD Sheba Medical Center, Ramat-Gan, Israel Gastro-Intestinal Malignancies - Part II 08.20-08.40 Current Treatment of Advanced Pancreatic Moderators: Sofia Man, MD Cancer Soroka Medical Center, Beer Sheva, Israel Talia Golan, MD Eyal Fenig, MD Sheba Medical Center, Ramat-Gan, Israel Davidoff Center, Rabin Medical Center, Petach Supported by AstraZeneca and MSD Tikva, Israel 08.40-09.00 Radiotherapy in Colorectal Cancer 10.45-11.05 Current Treatment of Advanced HCC Ross Abrams, MD Ravit Geva, MD Hadassah Medical Center, Jerusalem, Israel Sourasky Medical Center, Tel-Aviv, Israel 09.00-09.20 Current Treatment of Metastatic Esophago- Supported by Roche Gastric Cancers 11.05-11.20 Best of GI 2019 Ayala Hubert, MD Valeria Seministy, MD Hadassah Medical Center, Jerusalem, Israel Rambam Medical Center, Haifa, Israel Supported by MSD 09.20-09.50 Pro & Con: Is There a Role for Radiotherapy in Pancreatic Cancer? Moderator: Katerina Shulman, MD Hillel Yaffe Medical Center,
Recommended publications
  • Scientific Program
    www.iscort.org.il Scientific Program 08.01.2019 - 12.01.2019, Eilat, Israel The Annual Meeting of The Israeli Society for Clinical Oncology and Radiation Therapy ISCORT wishes to express its gratitude to the following companies הוועדה המארגנת for their support of the 19th ISCORT Annual Meeting: Organizing Committee ISCORT 19 נשיא הכנס: :President פרופ׳ סלומון שטמר Platinum Sponsor Salomon M. Stemmer, MD Roche מזכירת הכנס: :Secretory ד״ר ולריה סמניסטי Gold Sponsor Valeria Semenysty, MD יו"ר הרדיותרפיה: :BMS Radiation Oncology Co-Chair פרופ׳ בן קורן MSD Ben W. Corn, MD הוועדה המדעית Silver Sponsor Scientific Committee ISCORT 19 Astellas יו"ר: פרופ׳ מיכל לוטם Astrazeneca Chairman: Michal Lotem, MD ד"ר אהרון אלון Boehringer Ingelheim Aaron Allen, MD ד"ר נועם אסנה Eli Lilly Noam Asna, MD ד"ר יאיר בר ISI Jair Bar, MD PhD ד"ר יהונתן כהן Novartis Yonathan Cohen, MD PhD פרופ׳ בן קורן Pfizer Ben W. Corn, MD ד"ר אלה עברון Rafa Ella Evron, MD ד"ר דניאלה כץ Daniela Katz, MD פרופ׳ גל מרקל Bronze Sponsor Gal Markel, MD PhD ד"ר אינה אוספובט AbbVie Inna Ospovat, MD ד"ר אביבית פאר Assuta Avivit Peer, MD ד"ר רות פרץ Bayer Ruth Perets, MD PhD Bolpharma ד"ר רפאל פפר Raphael Pfeffer, MD Dexcel Pharma ד"ר קרן רובינוב Keren Rouvinov, MD Isotopia ד"ר יקטרינה שולמן Katerina Shulman, MD Medison ד"ר אמיר זוננבליק Merck Amir Sonnenblick, MD ד"ר מרק ויגודה Nanostring Marc Wygoda, MD ד"ר אלונה זר Neopharm Alona Zer, MD ד"ר אביעד זיק Oncotest-Teva Aviad Zik, MD Perrigo החברה המארגנת Sanofi Organizing Company א.מ.
    [Show full text]
  • Israel Endocrine Society
    Israel Endocrine Society Israel Endocrine Society Conference Browse the program for the upcoming event By Session All Sessions By ID 4 By Day Tuesday By Author Aizic, A. - 31 Now Viewing: All Sessions Note: The presenter's name is in bold Registration Tuesday Morning Date: Tuesday, April 9, 2013 Time: 7:30 AM - 8:00 AM Location: Oral Presentations I: Diabetes, Obesity and Metabolism Date: Tuesday, April 9, 2013 Time: 8:00 AM - 10:00 AM Location: Bareket Hall Session Chair: Benjamin Glaser Session Chair: Hannah Kanety 8:00 AM - AMPK corrects ER morphology and function in stressed pancreatic beta-cells via regulation of the ER resident protein DRP1 (ID: 25) Jakob Wikstrom (Israel) Tal Israeli (Israel) Etty Bachar-Wikstrom (Israel) Yafa Ariav (Israel) Erol Cerasi (Israel) Gil Leibowitz (Israel) 8:15 AM - Paradox In Metabolic Homeostasis: AHNAK Knockout Mice Are Resistant To Diet-Induced Obesity And Yet They Display Reduced Insulin Sensitivity (ID: 47) Maya Ramdas (Israel) Chava Harel (Israel) Natalia Krits (Israel) http://www.xcdsystem.com/ies2013/Program/index.cfm[05/04/2013 11:15:55] Israel Endocrine Society Michal Armoni, Rambam Medical Center (Israel) Eddy Karnieli, Institute of Endocrinology, Metabolism and Diabetes (Israel) 8:30 AM - Neonatal Wolfram syndrome: novel De-novo dominant mutation presenting as an unusual clinical phenotype (ID: 52) Abdulsalam Abu-Libdeh, Hadassah Hebrew University Hospital (Israel) 8:45 AM - Importance of maintaining redox potential balance in the development of type 2 diabetes (ID: 61) Tovit Rosenzweig,
    [Show full text]
  • Dear Colleagues, It Is Our Pleasure to Invite You to the Annual Meeting Of
    Dear Colleagues, It is our pleasure to invite you to the Annual Meeting of the Israel Neurosurgical Society which will be held at the Galilion Hotel, Israel. Although the main focus of the meeting will be Brain Tumors, the organizers will be happy to consider interesting talks on related subjects. Confirmed speakers to date that will share their experiences and update us in the latest developments include: Prof. Volker A. Coenen Dept. of Stereotactic and Functional Neurosurgery, University of Freiberg; Neurosurgery Clinic, Freiberg, Germany Prof. Garth Rees Cosgrov Dept. of Neurological Surgery, Brigham and Women's Hospital, Boston, MA, USA Prof. Hans Henkes Neuroradiological Clinic, Katharinenhospital, Stuttgart, Germany Prof. Robert H. Rosenwasser Dept. of Neurological Surgery, Jefferson Hospital for Neuroscience, Philadelphia, PA, USA As in previous meetings, we hope that this event will provide the opportunity to reconnect and meet with colleagues and to strengthen professional and personal ties among our members. We hope that you will be able to join us. Sincerely, Prof. Yigal Shoshann Prof. Mony Benifla Dr. Racheli Grossman President Secretary Treasurer 1 TENTATIVE TIMETABLE Wednesday, May 13, 2020 Light Lunch Afternoon Sessions Dinner Evening Social Event Thursday, May 14, 2020 Morning Sessions Lunch Afternoon Sessions Dinner Evening Social Event Friday, May 15, 2020 Morning Sessions Afternoon Sessions End and Light Lunch Meeting Secretariat Target Conferences Ltd. PO Box 51227, Tel Aviv 6713818, Israel Tel: +972 3 5175150, Fax: +972 3 5175155 e-mail: [email protected] www.israelneurosurgery.com 2 SCIENTIFIC ADVISORY COMMITTEE ON FUNCTIONAL NEUROSURGERY AND EPILEPSY Zvi Israel - Lead Advisor Dept. of Neurosurgery, Hadassah Hebrew University Medical Center, Jerusalem Roberto Spiegelmann Dept.
    [Show full text]
  • Conference Time Table
    CONFERENCE TIME TABLE 6 April 7-8, 2019, Hilton Tel Aviv Hotel The 48th Annual Meeting of the Israel Endocrine Society PROGRAM AT A GLANCE Sunday, April 7, 2019 15:30-15:50 Coffee Break 07:30-08:30 Registration and Gathering 15:50-16:50 Meet the Expert Hall A Meet the Expert Hall B Novel Avenues in the Management of Endocrine Hypertension 08:30-10:00 Parallel Oral Presentations Congenital Adrenal Hyperplasia Felix Beuschlein Thyroid Reproduction Obesity, Metabolic Syndrome Nils P Krone University Hospital of Zurich Chairs: Dania Hirsch, Chairs: Talia Geva Eldar, Chairs: Yonit Marcus- Perlman, Sheffield, UK Carlos Benbassat Joseph Orly Rosane Abramof-Ness 16:50-17:30 IES Members General Assembly Hall A Hall A Hall B Hall C Executive Committee Report 10:00-10:20 Coffee Break Accountant Report 10:20-11:20 Poster Session Poster Hall Prize lectures Hall A 11:20-12:10 Chair: Avraham Karasik Lindner Prize, Eyal Robenshtok Chowers Prize, Yael Riahi Outstanding Community Physician Award, Elizabeta Baron Plenary lecture 1 Hall A Fat in the Blood, Fat in the Heart 12:10-13:00 Ira Goldberg, NYU School of Medicine, NYU Langone Health Chair: Hannah Kanety 13:00-14:00 Lunch 14:00-15:30 Parallel Symposia Symposium 1 Hall A Symposium 2 Hall B Congenital Adrenal Hyperplasia (CAH) Big Data – Digital Health in in 2019 Endocrinology Chairs: Naomi Weintrob, David Zangen Chairs: Moshe Phillip, Irit Hochberg 14:00-14:30 Nils P Krone Varda Shalev Molecular Pathogenesis of Rare Forms Big Data: From Research to Value of CAH Director of research and innovation institute Academic Unit of Child Health Maccabi and Morris Kahn.
    [Show full text]
  • Recurrent Deep Venous Thrombosis in a Patient with Agenesis of Inferior Vena Cava
    International Journal of General Medicine Dovepress open access to scientific and medical research Open Access Full Text Article CASE REPORT Recurrent deep venous thrombosis in a patient with agenesis of inferior vena cava William Nseir1 Background: Agenesis of the inferior vena cava (IVC) as a cause of recurrent deep vein Mahmud Mahamid1 thrombosis (DVT) is uncommon. Zuhair Abu-Rahmeh2 Case: A 33-year-old male with no family history of thrombophilia, who had experienced mul- Arieh Markel3,4 tiple recurrent episodes of DVT over a 15-year period of unknown cause, was admitted into our hospital because of cellulitis in the right leg. Computer tomography with contrast of the 1Department of Internal Medicine, 2Radiology Department, Holy abdomen showed an absence of IVC. Family Hospital, Nazareth, Israel; Conclusion: Congenital absence of the IVC could be a rare risk factor for idiopathic DVT, 3 Department of Internal Medicine A, especially in young individuals. Haemek Medical Center, Afula, Israel; 4Technion, Faculty of Medicine, Haifa, Keywords: deep vein thrombosis, agenesis, inferior vena cava Israel Background Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, has an incidence of 1 to 3 per 1000 individuals per year in Western populations.1 Congenital anomalies of the inferior vena cava (IVC) are uncommon, and have been associated with the development of venous thrombosis of the lower limbs.2 Congenital anomalies of the IVC has been reported as a risk factor for DVT, especially in individuals ,30 years old, and a concomitant thrombophilic disorder has been found in such individuals.3 We report a case of recurrent DVT in a 33-year-old man with agenesis of the IVC.
    [Show full text]
  • 0201 Haplotype on the Risk for Multiple Sclerosis in Diverse Arab Populations in Israel
    Genes and Immunity (2010) 11, 423–431 & 2010 Macmillan Publishers Limited All rights reserved 1466-4879/10 www.nature.com/gene ORIGINAL ARTICLE Opposing effects of the HLA-DRB1*0301-DQB1*0201 haplotype on the risk for multiple sclerosis in diverse Arab populations in Israel G Benedek1,6, T Paperna2,6, N Avidan2, I Lejbkowicz2, JR Oksenberg3, J Wang3, C Brautbar1,4, S Israel4 and A Miller2,5, for the Israeli MS Genetics group7 1The Lautenberg Center for Immunology, Hebrew University Hadassah Medical School, Jerusalem, Israel; 2Faculty of Medicine, Rappaport Research Institute, Technion–Israel Institute of Technology, Haifa, Israel; 3Department of Neurology, University of California, San Francisco, CA, USA; 4Tissue Typing and Immunogenetics Unit, Hadassah Medical Center, Jerusalem, Israel and 5Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel Different multiple sclerosis (MS) prevalence rates were reported for Muslim and Christian Arabs in Israel. In this study, we evaluated whether associations of human leukocyte antigen (HLA) genes with MS may contribute to this prevalence difference. DNA samples from Israeli Arab MS patients (n ¼ 109) and controls (n ¼ 132) were typed for HLA class I (HLA-A, -B and -C) and II (HLA-DRB1 and -DQB1) genes. Global comparisons of HLA allele frequencies revealed significant differences between Christians and Muslims; therefore, case–control analyses were stratified by religious affiliation. Disease characteristics of Muslim and Christian Arab MS patients were similar to those reported for European populations. Opposing association signals with MS were observed for alleles composing the DRB1*0301-DQB1*0201 haplotype: positive association of the HLA- DRB1*0301 allele in Muslims (PBonferroni ¼ 0.004, odds ratio (OR) ¼ 3.07), and negative association in Christian Arabs (PBonferroni ¼ 0.01, OR ¼ 0.12), with similar results obtained for HLA-DQB1*0201.
    [Show full text]
  • The Right Atrium of Patients with Various Heart Diseases Retain Progenitor Cells with Regenerative Capacity
    S7 - Prognosis and Outcome in Heart Failure The Right Atrium of Patients with Various Heart Diseases Retain Progenitor Cells with Regenerative Capacity Ayelet Itzhaki-Alfia 1, Jonathan Leor 1,Shiri Netser1, Leonid Sternik 2, Dan Spiegelstein 2, David Mishaly 2, Jacob Lavee 2, Ehud Raanani 2,Barbash Israel M3 1 Neufeld Cardiac Research Institute, Sackler Faculty of Medicine,Tel-Aviv University, 2 Department of Cardiothoracic Surgery, 3 Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 37 S7 - Prognosis and Outcome in Heart Failure The Impact of the NT-proBNP Assay in the Emergency Department on the Diagnosis of Heart Failure and on Outcomes in Patients Admitted for Dyspnea: A Prospective Randomized Placebo-controlled Double-center Trial (BNP4EVER) Simcha Meisel 1, Margarita Medvedovski 2, Moshe Sharist 3, Jalal Ashkar 2,Pavel Pschianski2, Michael Glikson 4, Shmuel Bar Haim 3, Michael Shochat 1, David Blondheim 1, Avraham Shotan 1 1 Heart Institute, Hillel Yaffe Medical Center, 2 Emergency Department, Hillel Yaffe Medical Center, Hadera, 3 Emergency Department, Assaf Harofeh Medical Center, Zerifin, 4 Heart Institute, Chaim Sheba Medical Center, Hadera, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 38 S7 - Prognosis and Outcome in Heart Failure Echocardiographic and Plasma N-Terminal Pro-B Type Natriuretic Peptide Evaluation During Pregnancy in Patients with Preexisting Dilated Cardiomyopathy Alex Blatt 1,Ilya Litovchik1, Ricardo
    [Show full text]
  • Curriculum Vitae – Barak Zafrir
    Curriculum Vitae – Barak Zafrir PERSONAL DETAILS Date Prepared: November 2016 Name: BARAK ZAFRIR Office Address: Cardiovascular Department, Lady Davis Carmel Medical Center 7 Michal St., Haifa, Israel. Home Address: 6/6 Moshe Dayan St. , Kiryat Tiveon , Israel Phone: +972-0522541577 Email: [email protected] FAX: +972-99560390 Place of Birth: ISRAEL Date of Birth June 11, 1974 Marital Status Married; 2 Children ACADEMIC DEGREES Faculty of Medicine, Technion, 1996-2002 M.D Medicine Israel Institute of Technology, Haifa, Israel. PROFESSIONAL EXPERIENCE 2015-present Director, Cardiac Prevention and Rehabilitation Service Carmel Medical Center, Haifa, Israel 2013-present Preventive Cardiology / Lipid Clinics (a) Carmel Medical Center, Haifa, Israel. (b) Acre, Clalit Health Services, Haifa and Western Galilee District. 1 2012-2013 Advanced Clinical/Research Fellowship: Preventive Cardiology and Cardio-metabolic Diseases Brigham & Women's Hospital, Harvard Medical School, Boston, USA, [Fellowship Director: Jorge Plutzky M.D] 2010-present Staff Cardiologist Cardiovascular Department, Carmel Medical Center, Haifa, Israel 2004-2010 Residency and Fellowship: Internal Medicine and Cardiology Carmel Medical Center, Haifa, Israel. 2003 Internship: Medicine and Surgery HaEmek Medical Center, Afula, Israel. PROFESSIONAL COURSES Oct. 2016 Advanced Course on Familial Hypercholesterolemia, European Atherosclerosis Society, Greece Dec. 2015 Hyperlipidemia Academy, Amgen Co., Geneva, Switzerland. Nov. 2014 Cardiopulmonary Exercise Testing Training Course,
    [Show full text]
  • Scientific Program
    The 63th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery April 12-13 • 2016 • Tel Aviv, Israel SCIENTIFIC PROGRAM Paragon Israel (Dan Knassim) Paragon Tel/Fax:03-5767730/7 Israel (Dan Knassim) a Paragon Group Company [email protected] TUESDAY, APRIL 12, 2016 08:30-10:00 Interventional Cardiology I Hall A Chairs: Ariel Finkelstein, Ran Kornowski, Israel 08:30 Effect of Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes: a propensity score-matched analysis Amos Levi1,2, Tamir Bental1,2, Hana Veknin Assa1,2, Gabriel Greenberg1,2, Eli Lev1,2, Ran Kornowski1,2, Abid Assali1,2 1Cardiology, Rabin Medical Center, Israel 2Sackler Faculty of Medicine, Tel Aviv University, Israel 08:41 Percutaneous Valve-in-Valve Implantation for the Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Degeneration Uri Landes1, Abid Assali1, Ram Sharoni1,2, Hanna Vaknin-Assa1, Katia Orvin1, Amos Levi1, Yaron Shapira1, Shmuel Schwartzenberg1, Ashraf Hamdan1, Tamir Bental1, Alexander Sagie1, Ran Kornowski1 1Department of Cardiology, Rabin Medical Center, Tel Aviv, Israel 2Department of Cardiac Surgery, Rabin Medical Center, Tel Aviv, Israel 08:52 Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient Characteristics, Procedural Issues and Clinical Outcome Uri Landes1, Alon Barsheshet1, Abid Assali1, Hanna Vaknin-Assa1, Israel Barbash3, Victor Guetta3, Amit Segev3, Ariel Finkelstein2, Amir Halkin2, Jeremy Ben-Shoshan2,
    [Show full text]
  • Curriculum Vitae Shay Schneider, M.D
    April, 2020 Curriculum Vitae Shay Schneider, M.D Name: Shay Schneider Date of birth: December 23, 1979 Place of birth: Tel Aviv, Israel Family status: Married +2 Telephone: +972-54-7685189 E mail: [email protected] CLINICAL EXPERIENCE Sep 2018-present: Senior staff member Otolaryngology department, Soroka University Medical Center, Beer Sheva, Israel. Sep 2018-Sep 2020: Clinical Fellow (Rhinology and skull base surgery), A.R.M, Center of Otolaryngology/ Head and Neck Surgery, Assuta Medical Center, Tel Aviv, Israel. Sep 2012-Sep 2018: Resident: Otolaryngology department, Soroka University Medical Center, Beer Sheva, Israel. Jan 2011 - Jan 2012: Rotating internship year: Training physician in internal medicine, general surgery, anesthesia and pediatrics units, Barzilai Medical Center in Ashkelon, Israel. Jun 2009 - Aug 2009: Clinical rotation in Otolaryngology, Shaare Zedek Medical Center in Jerusalem, Israel. ACADEMIC DEGREES 2016- present: Instructor, Faculty of Health Sciences, Ben Gurion University, Beer Sheva, Israel. 2004-2010: MD degree, Third Medical Faculty, Charles University in Prague (English program), Czech Republic. POST ACADEMIC COURSES Jan 2020: Baloon sinuplasty and Eustachian tuboplasty, Madeira, Portugal. Aug-Sep 2018: Observership, University of Texas MD Anderson Cancer Center, Houston, Texas. United States 2013-2018: School of Continuing Studies, Otolaryngology program, The Sackler Faculty of Medicine, Tel Aviv University, Israel. June 2017: Rhinoplasty course, Ziv Medical Center, Israel Feb 2017: 4th Annual OSAS International Surgery Course, Florida Hospital Nicholson Center & Florida Hospital Celebration Health, Celebration, United States. Feb 2017: Trans- oral laser surgery (TLS) course, Kaplan Medical Center. Sep 2016: Head and neck dissection course, Tel Aviv University. Oct 2014: Sedation course, Sheba Medical Center, Tel Aviv.
    [Show full text]
  • Antibiotic Treatment for Invasive Listeriosis and Patient
    Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality.
    [Show full text]
  • Prospective Longitudinal Trends in Body Composition and Clinical Outcomes 3 Years Following Sleeve Gastrectomy
    Obesity Surgery (2019) 29:3833–3841 https://doi.org/10.1007/s11695-019-04057-2 ORIGINAL CONTRIBUTIONS Prospective Longitudinal Trends in Body Composition and Clinical Outcomes 3 Years Following Sleeve Gastrectomy Shiri Sherf-Dagan1,2,3 & Shira Zelber-Sagi1,4 & Assaf Buch5,6 & Nir Bar1,2 & Muriel Webb1 & Nasser Sakran7,8,9 & Asnat Raziel7 & David Goitein2,7,10 & Andrei Keidar11 & Oren Shibolet1,2 Published online: 11 July 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Background and Aims Longitudinal assessment of body composition following bariatric surgery allows monitoring of health status. Our aim was to elucidate trends of anthropometric and clinical outcomes 3 years following sleeve gastrectomy (SG). Methods A prospective cohort study of 60 patients who underwent SG. Anthropometrics including body composition analysis measured by multi-frequency bioelectrical impedance analysis, blood tests, liver fat content measured by abdominal ultrasound and habitual physical activity were evaluated at baseline and at 6 (M6), 12 (M12), and 36 (M36) months post-surgery. Results Sixty patients (55% women, age 44.7 ± 8.7 years) who completed the entire follow-up were included. Fat mass (FM) was reducedsignificantly1yearpost-surgery(55.8±11.3to26.7±8.3kg;P < 0.001) and then increased between 1 and 3 years post- operatively, but remained below baseline level (26.7 ± 8.3 to 33.1 ± 11.1 kg; P < 0.001). Fat free mass (FFM) decreased significantly during the first 6 months (64.7 ± 14.3 to 56.9 ± 11.8 kg; P < 0.001), slightly decreased between M6 and M12 and then reached a plateau through M36.
    [Show full text]